Phase 2 Readout
IMRX: Phase 2 Readout: atebimetinib
December 31, 2026 · atebimetinib. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- December 31, 2026
- Company
- Immuneering Corp (IMRX)
- Drug
- atebimetinib
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Readout~quarter
Phase 2 Readout: atebimetinib
- Company
- Immuneering Corp (IMRX)
- Drug
- atebimetinib
- Indication
- first-line pancreatic cancer